Loading
Vitruviae
Vitruviae develops immune therapies that recognise sugars and fats found on the surface of cancer cells. Its first medicine, VTRU200, is planned for an early trial in acute myeloid leukaemia and other blood cancers and solid tumours.
Overview
Vitruviae is based in Nutley, New Jersey, and develops precision immunotherapies aimed at tumour-associated glycans and lipids. VTRU200 is a humanised trispecific T cell engager that binds CD3 on T cells and tumour-associated glycans and lipids; the company is prioritising it for acute myeloid leukaemia. The phase 1/2a trial NCT07749976 in adults and children with relapsed or refractory acute myeloid leukaemia, high-risk myelodysplastic syndrome, diffuse large B-cell lymphoma after CAR-T failure and advanced solid tumours is registered as not yet recruiting. Other programmes listed are VTRU300 (a trispecific NK cell engager), VCAR300 (a CAR-T cell) and VRAD600 (a radiotheranostic). Its first registered cancer trial, NCT07749976, was posted on ClinicalTrials.gov in August 2026.
Notes
- Founding year not stated on the company website.
- No financing amounts or investors stated on the website; grants listed there relate to collaborators and other research.
- Company website and registry record read on 29 October 2026.
Connected
7Similar pages
- CompanyChiome Bioscience
Shares Trispecific antibodies, T-cell engagers (bispecific).
- CompanyExcalipoint Therapeutics
Shares Trispecific antibodies, T-cell engagers (bispecific).
- TrialA Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
- CompanyRemedy Plan Therapeutics
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
- CompanyShine-On Biomedical
Shares Trispecific antibodies, CD3, T-cell engagers (bispecific).
- TrialFirst-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients
Shares Higher-risk myelodysplastic syndromes, Acute myeloid leukaemia.
- CompanyCullinan Therapeutics
Shares CD3, T-cell engagers (bispecific), Acute myeloid leukaemia.
- CompanyJanux Therapeutics
Shares CD3, T-cell engagers (bispecific).
Sources
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
ClinicalTrials.gov · 1
vitruviae.com · 1
A source that has moved or gone is reported by the weekly link check. /audit/